DexCom, Inc. is a medical device company focused on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health. The company’s primary products include the Dexcom G7 and Dexcom G7 15 Day integrated CGM systems, the Dexcom G6 system, and the Dexcom ONE+ system for the European market. In August 2024, the company launched Stelo, an over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin. DexCom also provides the Dexcom Share remote monitoring system and the Dexcom Follow app, which allow patients to securely transmit glucose data to designated recipients. The company’s software platform, Dexcom Clarity, offers cloud-based reporting and data analysis. DexCom serves patients, caregivers, and clinicians globally, with specific regulatory clearances in the United States and the European Union. The company collaborates with various partners to integrate its CGM technology with insulin pumps, smart insulin pens, and other digital health applications, including Apple Watch and Garmin devices. Founded in 1999, DexCom commercialized its first FDA-approved product in 2006.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Devices Homepage dexcom.com
Sector Healthcare IR page investors.dexcom.com
Tags
continuous glucose monitoring, diabetes management, metabolic health, glucose biosensors, remote monitoring, insulin delivery integration, medical software, over-the-counter diagnostics, Dexcom G7, Dexcom G7 15 Day, Dexcom G6, Dexcom ONE+, Stelo, Dexcom Share, Dexcom Follow, Dexcom Clarity
Press page investors.dexcom.com/news/default.aspx

Metrics

Valuation  
Market cap $ 31.131B
Market cap (USD) $ 31.131B
P/E 32.86
PEG 0.94
P/BV 12.28
P/S 6.10
P/OCF 22.01
P/FCF 28.34
Dividend yield —
Turnover / mcap —
Returns  
ROE 34.5%
ROI 21.0%
ROIC 17.6%
Profit margin 17.9%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 34.8%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity 45.2%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 62
Quality score 38.9%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005
Revenue 4.662B 4.033B 3.622B 2.91B 2.449B 1.927B 1.476B 1.032B 718.5M 573.3M 402M 259.2M 160M 99.9M 76.266M 48.631M 29.693M 9.838M — — —
Net profit 836.3M 576.2M 541.5M 341.2M 154.7M 493.6M 101.1M -127.1M -50.2M -65.6M -57.6M -22.4M -29.8M -54.5M -44.746M -55.17M -53.524M -55.184M -45.878M -46.599M —
Free cash flow 1.077B 630.7M 511.9M 304.7M 53.3M 276.6M 134.5M 56.1M 26M 500K 15.7M 7.4M -5.5M -42.6M -38.132M -49.536M -42.381M -39.943M -36.65M -47.087M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005
Share price 66.37 77.77 124.09 113.24 536.95 369.72 218.74 119.8 57.39 59.7 81.9 55.05 35.41 13.59 9.31 11.85 7.15 1.53 7.1 11.7 14.58
Price performance 12m -0.15 -0.37 0.1 -0.79 0.45 0.69 0.83 1.09 -0.04 -0.27 0.49 0.55 1.6 0.46 -0.21 0.66 3.66 -0.78 -0.39 -0.2 —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 102M 134M 227M 286M 429M 514M 713M 974M 1.01B 1.22B
↳ YoY growth +37.2% +32.1% +68.8% +26.3% +49.7% +20.0% +38.7% +36.5% +3.3% +20.9%
↳ 5y CAGR +46.5% +42.0% +38.3% +39.6% +33.8% +28.6% +23.2%
Lease liabilities (USD) — — 0.00 101M 181M 179M 179M 165M 152M 156M
Cash and deposits (USD) 94.5M 442M 1.14B 446M 818M 1.05B 642M 566M 606M 918M
Intangible assets (USD) 200,000 — — — — 31.5M 173M 135M 103M 70.8M
Right-of-use assets (USD) — — 0.00 71.5M 93.3M 88.1M 80M 71.4M 62.8M 77.4M
Cash flow detail
Operating cash flow (USD) 56.2M 92M 123M 315M 476M 443M 670M 749M 990M 1.44B
Purchases of property, plant and equipment (USD) -55.7M -66M -67.1M -180M -199M -389M -365M -237M -359M -364M
Change in receivables (cash effect) (USD) -27.2M -31.8M -93.2M -60M -142M -75.5M -200M -260M -35M -202M
Change in inventories (cash effect) (USD) -9.8M 400,000 -25.5M -49.1M -115M -112M 49.3M -253M 12.4M -63.7M
Change in payables (cash effect) (USD) 21.1M 21.1M 56.2M 109M 195M 58M 295M 467M 212M 347M
Share buybacks (cash effect) (USD) 0.00 0.00 -100M 0.00 0.00 0.00 -558M -689M -750M -500M
Interest paid (cash effect) (USD) -100,000 -2.4M -3.6M -10.4M -10.6M -11.6M -12.2M -12.4M -11.4M -11.4M
Income taxes paid (cash effect) (USD) -100,000 -1.4M -2.3M -4.8M -3.6M -16.8M -114M -212M -198M -94.4M
Share-based compensation (USD) 111M 106M 102M 103M 119M 113M 127M 151M 170M 160M
Operating cash flow before change in receivables (USD) 83.4M 124M 216M 375M 618M 518M 869M 1.01B 1.02B 1.64B
Free cash flow (OCF - PPE - intangibles) (USD) 500,000 26M 56.1M 135M 277M 53.3M 305M 512M 631M 1.08B
Income detail
Research and development expense (USD) 156M 185M 200M 274M 360M 517M 484M 506M 552M 599M
↳ 5y CAGR +38.4% +36.2% +34.8% +31.6% +21.2% +27.1% +21.2% +20.4% +15.1% +10.7%
Total comprehensive income (USD) -66.3M -51.8M -123M 102M 495M 152M 329M 536M 585M 959M
Comprehensive income to owners (USD) -66.3M -51.8M -123M 102M 495M 152M 329M 536M 585M 959M
Reported Feb 21, 2019 Feb 21, 2019 May 1, 2019 Feb 13, 2020 Feb 11, 2021 Feb 9, 2023 Feb 9, 2023 Feb 8, 2024 Feb 18, 2025 Feb 12, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Dexcom Reports Third Quarter 2026 Financial Results Bull 5 Bear 0 Results

October 29, 2026

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2026.

Third Quarter 2026 Financial Highlights:

  • Revenue grew 11% year-over-year to $1.344 billion on a reported basis and 11% year-over-year on an organic 1 basis.
  • U.S. revenue grew 14% and international revenue grew 5% on a reported basis and 5% on an organic 1 basis, all on a year-over-year basis.
  • GAAP operating income of $327.2 million or 24.3% of revenue, an increase of 420 basis points compared to the third quarter of 2025. Non-GAAP operating income* of $339.5 million or 25.3% of reported revenue, an increase of 270 basis points compared to the third quarter of 2025.

Third Quarter 2026 Strategic Highlights:

  • Subsequent to the quarter, published the CONNECT randomized clinical trial in The New England Journal of Medicine, showcasing outcomes driven by Dexcom G7 that redefine the standard of care for people with Type 2 diabetes not on insulin.
  • Launched the fully redesigned Stelo experience, with enhanced glucose insights, simplified meal logging, and more detailed nutritional information.
  • Advanced the rollout of the Dexcom G7 15 Day System in the U.S. and secured first two G7 15 Day international regulatory clearances, positioning for continued momentum in the transition of the global base to the extended wear platform.

“This quarter, we continued to build momentum across the business, delivering strong revenue growth and margin progression, strengthening our clinical evidence, and advancing key product and operational initiatives,” said Jake Leach, Dexcom’s president and CEO. “This performance enabled us to again raise our full-year revenue and operating margin guidance and reinforces our confidence in our ability to deliver on the long-term objectives we outlined at Investor Day.”

2026 Annual Guidance

Dexcom is raising the midpoint of fiscal year 2026 Revenue guidance, reiterating fiscal year 2026 Non-GAAP Gross Profit Margin guidance, and increasing fiscal year 2026 guidance for Non-GAAP Operating Margin and Adjusted EBITDA Margin to the following levels:

  • Revenue of $5.20 - $5.25 billion (approximately 12-13% growth)
  • Non-GAAP Gross Profit Margin of approximately 64%
  • Non-GAAP Operating Margin of approximately 24%
  • Adjusted EBITDA Margin of approximately 32%

The company also announced a share repurchase authorization of up to $1.0 billion in conjunction with third quarter results.

____________________
1 Third quarter 2026 organic revenue was $1.346 billion and excludes $1.7 million of foreign exchange impact and $0.7 million of acquired non-CGM revenue.

Third Quarter 2026 Financial Results

Revenue: In the third quarter of 2026, worldwide revenue grew 11% to $1.344 billion on a reported basis, up from $1.209 billion in the third quarter of 2025.

Gross Profit: GAAP gross profit totaled $864.4 million or 64.3% of revenue for the third quarter of 2026, compared to $731.4 million or 60.5% of revenue in the third quarter of 2025.

Non-GAAP gross profit* totaled $875.3 million or 65.1% of reported revenue for the third quarter of 2026, compared to $741.3 million or 61.3% of reported revenue in the third quarter of 2025.

Operating Income: GAAP operating income for the third quarter of 2026 was $327.2 million or 24.3% of revenue, compared to GAAP operating income of $242.5 million or 20.1% of revenue for the third quarter of 2025.

Non-GAAP operating income* for the third quarter of 2026 was $339.5 million or 25.3% of reported revenue, compared to non-GAAP operating income of $272.9 million or 22.6% of reported revenue for the third quarter of 2025.

Net Income and Diluted Net Income Per Share: GAAP net income was $275.1 million, or $0.72 per diluted share, for the third quarter of 2026, compared to GAAP net income of $283.8 million, or $0.70 per diluted share, for the third quarter of 2025.

Non-GAAP net income* was $275.0 million, or $0.73 per diluted share, for the third quarter of 2026, compared to non-GAAP net income of $242.5 million, or $0.61 per diluted share, for the third quarter of 2025. The third quarter 2026 non-GAAP net income excludes $11.9 million of amortization of intangible assets, $0.4 million of business transition and other significant items, and $12.4 million of tax adjustments.

Cash and Liquidity: As of September 30, 2026, Dexcom held $1.82 billion in cash, cash equivalents and marketable securities and our revolving credit facility remains undrawn. The cash balance represents significant financial and strategic flexibility as Dexcom continues to expand production capacity and explore new market opportunities.

* See Table D below for a reconciliation of these GAAP and non-GAAP financial measures.

Conference Call

Management will hold a conference call today starting at 4:30 p.m. (Eastern Time). The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com by navigating to “Events and Presentations,” and will be archived for future reference. To listen to the conference call, please dial (888) 414-4585 (U.S./Canada) or (646) 960-0331 (International) and use the confirmation ID “9430114” approximately five minutes prior to the start time.

Statement Regarding Use of Non-GAAP Financial Measures

This press release and the accompanying tables include non-GAAP financial measures. For a description of these non-GAAP financial measures, including the reasons management uses each measure, and reconciliations of these non-GAAP financial measures to the most directly comparable financial measures prepared in accordance with generally accepted accounting principles in the United States (GAAP), please see the section titled “About Non-GAAP Financial Measures” below as well as the related Table D. We have not reconciled our organic revenue growth, Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin, and Adjusted EBITDA Margin estimates for fiscal year 2026 because certain items that impact these figures are uncertain or out of our control and cannot be reasonably predicted. Accordingly, reconciliations of our organic revenue growth, Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin and Adjusted EBITDA Margin estimates are not available without unreasonable effort.

About DexCom, Inc.

Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

Dexcom. Discover what you’re made of. For more information, visit www.dexcom.com .

Category: IR

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements that are not purely historical regarding Dexcom’s or its management’s intentions, beliefs, expectations and strategies for the future, including those related to Dexcom’s future operating results and financial position, including estimated Revenue, Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin, and Adjusted EBITDA Margin for fiscal year 2026, and expected growth rates as compared to the year ended December 31, 2025; future expenses and investments; and potential business plans and opportunities. All forward-looking statements included in this press release are made as of the date of this press release, based on information currently available to Dexcom as of the date hereof. Forward-looking statements deal with future events and are therefore subject to various risks and uncertainties. Actual results could differ materially from those anticipated in these forward-looking statements. The risks and uncertainties that may cause actual results to differ materially from Dexcom’s current expectations are more fully described in the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Dexcom’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings filed with the Securities and Exchange Commission. Except as required by law, Dexcom assumes no obligation to update any such forward-looking statement after the date of this communication or to conform these forward-looking statements to actual results.

DexCom, Inc.Table AConsolidated Balance Sheets(In millions, except par value data)(Unaudited)
September 30, 2026 December 31, 2025
Assets
Current assets:
Cash and cash equivalents $ 961.4 $ 917.7
Short-term marketable securities 856.5 1,081.0
Accounts receivable, net 1,186.2 1,216.1
Inventory 770.7 629.1
Prepaid and other current assets 141.2 189.4
Total current assets 3,916.0 4,033.3
Property and equipment, net 1,543.1 1,559.9
Operating lease right-of-use assets 83.7 77.4
Goodwill 24.0 24.2
Intangibles, net 89.4 70.8
Deferred tax assets 305.4 295.6
Other assets 277.2 278.7
Total assets $ 6,238.8 $ 6,339.9
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable and accrued liabilities $ 2,065.6 $ 1,944.0
Accrued payroll and related expenses 159.7 169.2
Short-term operating lease liabilities 20.7 21.6
Other current liabilities 6.6 7.7
Total current liabilities 2,252.6 2,142.5
Long-term senior convertible notes 1,243.7 1,240.9
Long-term operating lease liabilities 77.5 73.4
Other long-term liabilities 129.6 137.1
Total liabilities 3,703.4 3,593.9
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value, 5.0 million shares authorized; no shares issued and outstanding at September 30, 2026 and December 31, 2025 — —
Common stock, $0.001 par value, 800.0 million shares authorized; 412.7 million and 373.0 million shares issued and outstanding, respectively, at September 30, 2026; and 410.7 million and 384.8 million shares issued and outstanding, respectively, at December 31, 2025 0.4 0.4
Additional paid-in capital 2,425.3 2,281.5
Accumulated other comprehensive income 85.5 115.0
Retained earnings 3,157.6 2,433.9
Treasury stock, at cost; 39.7 million shares at September 30, 2026 and 25.9 million shares at December 31, 2025 (3,133.4 ) (2,084.8 )
Total stockholders’ equity 2,535.4 2,746.0
Total liabilities and stockholders’ equity $ 6,238.8 $ 6,339.9
DexCom, Inc.Table BConsolidated Statements of Operations(In millions, except per share data)(Unaudited)
Three Months EndedSeptember 30, Nine Months EndedSeptember 30,
2026 2025 2026 2025
Revenue $ 1,344.5 $ 1,209.3 $ 3,844.8 $ 3,402.4
Cost of sales 480.1 477.9 1,400.1 1,393.2
Gross profit 864.4 731.4 2,444.7 2,009.2
Operating expenses:
Research and development 161.6 157.5 459.9 450.9
Selling, general and administrative 375.6 331.4 1,084.0 969.5
Total operating expenses 537.2 488.9 1,543.9 1,420.4
Operating income 327.2 242.5 900.8 588.8
Other income, net 7.5 109.8 20.9 158.9
Income before income taxes 334.7 352.3 921.7 747.7
Income tax expense 59.6 68.5 198.0 178.7
Net income $ 275.1 $ 283.8 $ 723.7 $ 569.0
Basic net income per share $ 0.73 $ 0.73 $ 1.90 $ 1.45
Shares used to compute basic net income per share 374.7 391.1 380.6 391.4
Diluted net income per share $ 0.72 $ 0.70 $ 1.87 $ 1.42
Shares used to compute diluted net income per share 383.5 407.4 389.0 407.7
DexCom, Inc.Table CRevenue by Customer Sales Channel and Geographic Region(Dollars in millions)(Unaudited)
Three Months Ended September 30,
2026 2025
(In millions) United States International Total United States International Total
Distributor $ 933.1 $ 214.9 $ 1,148.0 $ 818.1 $ 207.9 $ 1,026.0
Direct 36.7 159.8 196.5 33.8 149.5 183.3
Total revenue $ 969.8 $ 374.7 $ 1,344.5 $ 851.9 $ 357.4 $ 1,209.3
Nine Months Ended September 30,
2026 2025
(In millions) United States International Total United States International Total
Distributor $ 2,623.5 $ 637.2 $ 3,260.7 $ 2,338.7 $ 545.1 $ 2,883.8
Direct 112.0 472.1 584.1 104.7 413.9 518.6
Total revenue $ 2,735.5 $ 1,109.3 $ 3,844.8 $ 2,443.4 $ 959.0 $ 3,402.4
DexCom, Inc.Table DItemized Reconciliation Between GAAP and Non-GAAP Financial Measures(In millions, except per share data)(Unaudited)
Three Months EndedSeptember 30, Nine Months EndedSeptember 30,
2026 2025 2026 2025
GAAP gross profit $ 864.4 $ 731.4 $ 2,444.7 $ 2,009.2
Amortization of intangible assets(1) 10.9 7.1 26.5 21.4
Business transition and other significant items(2) — 2.8 — 2.8
Non-GAAP gross profit $ 875.3 $ 741.3 $ 2,471.2 $ 2,033.4
GAAP operating income $ 327.2 $ 242.5 $ 900.8 $ 588.8
Amortization of intangible assets(1) 11.9 8.0 29.3 23.8
Business transition and other significant items(2) 0.4 22.7 2.1 24.8
Intellectual property litigation costs(3) — (0.3 ) — 0.4
Non-GAAP operating income $ 339.5 $ 272.9 $ 932.2 $ 637.8
GAAP net income $ 275.1 $ 283.8 $ 723.7 $ 569.0
Business transition and other significant items(2) 0.4 18.4 1.9 20.3
Depreciation and amortization 74.5 63.6 209.8 186.6
Intellectual property litigation costs(3) — (0.3 ) — 0.4
(Income) loss from equity investments — (82.7 ) 10.0 (78.1 )
Share-based compensation 36.8 45.1 119.1 124.6
Interest expense and interest income (11.2 ) (28.0 ) (41.5 ) (75.1 )
Income tax expense 59.6 68.5 198.0 178.7
Adjusted EBITDA $ 435.2 $ 368.4 $ 1,221.0 $ 926.4
GAAP net income $ 275.1 $ 283.8 $ 723.7 $ 569.0
Amortization of intangible assets(1) 11.9 8.0 29.3 23.8
Business transition and other significant items(2) 0.4 22.7 2.1 24.8
Intellectual property litigation costs(3) — (0.3 ) — 0.4
(Income) loss from equity investments — (82.7 ) 10.0 (78.1 )
Adjustments related to taxes(4) (12.4 ) 11.0 (4.7 ) 23.1
Non-GAAP net income $ 275.0 $ 242.5 $ 760.4 $ 563.0
DexCom, Inc.Table D (Continued)Itemized Reconciliation Between GAAP and Non-GAAP Financial Measures(In millions, except per share data)(Unaudited)
Three Months EndedSeptember 30, Nine Months EndedSeptember 30,
2026 2025 2026 2025
GAAP net income $ 275.1 $ 283.8 $ 723.7 $ 569.0
Interest expense on senior convertible notes, net of tax 1.6 2.8 4.9 8.6
GAAP net income used for diluted EPS, if-converted(5) $ 276.7 $ 286.6 $ 728.6 $ 577.6
Non-GAAP net income $ 275.0 $ 242.5 $ 760.4 $ 563.0
Interest expense on senior convertible notes, net of tax — 1.2 — 3.7
Non-GAAP net income used for diluted EPS, if-converted(5) $ 275.0 $ 243.7 $ 760.4 $ 566.7
GAAP diluted net income per share (5) $ 0.72 $ 0.70 $ 1.87 $ 1.42
Amortization of intangible assets(1) 0.03 0.02 0.08 0.06
Business transition and other significant items(2) — 0.06 0.01 0.06
Intellectual property litigation costs(3) — — — —
(Income) loss from equity investments — (0.21 ) 0.03 (0.20 )
Adjustments related to taxes(4) (0.03 ) 0.03 (0.01 ) 0.06
Impact of adjustment to GAAP diluted shares(6) 0.01 0.01 0.02 0.01
Non-GAAP diluted net income per share(5) (7) $ 0.73 $ 0.61 $ 1.99 $ 1.42
GAAP diluted weighted-average shares outstanding 383.5 407.4 389.0 407.7
Non-GAAP diluted weighted-average shares outstanding 375.8 399.7 381.3 400.0
Reconciliation of non-GAAP diluted weighted-average shares outstanding:
GAAP diluted weighted-average shares outstanding 383.5 407.4 389.0 407.7
Adjustment for dilutive impact of senior convertible notes due 2028(8) (7.7 ) (7.7 ) (7.7 ) (7.7 )
Non-GAAP diluted weighted-average shares outstanding 375.8 399.7 381.3 400.0
(1) Represents amortization of acquired intangible assets.
(2) For the three and nine months ended September 30, 2026, business transition and other significant items are primarily related to rent for vacated office space in San Diego, California. For the three and nine months ended September 30, 2025, business transition and other significant items are primarily related to workforce reduction costs associated with organizational realignment and rent for vacated office space in San Diego, California.
(3) We have excluded third-party attorney’s fees, costs, and expenses incurred by Dexcom exclusively in connection with Dexcom’s patent infringement litigation against Abbott Diabetes Care, Inc., as further described in the section titled “Legal Proceedings” in Dexcom’s Annual Report on Form 10-K for the year ended December 31, 2024.
(4) For the three and nine months ended September 30, 2026 and September 30, 2025, tax adjustments are primarily related to the tax effect of non-GAAP adjustments and shortfalls from share-based compensation for employees.
(5) When our senior convertible notes are dilutive on a GAAP or non-GAAP basis, net income used for calculating GAAP and non-GAAP diluted net income per share includes an interest expense add back, net of tax, under the if-converted method. In loss periods, basic and diluted net loss per share are the same since the effect of potential common shares is anti-dilutive and therefore excluded.
(6) The adjustments are for the transition from GAAP diluted net income per share to non-GAAP diluted net income per share due to our senior convertible notes.
(7) The sum of the non-GAAP per share components may not equal the totals due to rounding.
(8) We adjust for the dilutive effect of our senior convertible notes when the effect is not the same on a GAAP and non-GAAP basis for a given period.

ABOUT NON-GAAP FINANCIAL MEASURES

The accompanying press release dated October 29, 2026 contains non-GAAP financial measures. These non-GAAP financial measures include organic revenue, non-GAAP gross profit margin, non-GAAP operating income, non-GAAP operating margin, non-GAAP net income, non-GAAP diluted net income per share, and non-GAAP diluted weighted average shares outstanding, as well as Adjusted EBITDA.

We report non-GAAP financial measures in addition to, and not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP. We use these non-GAAP financial measures for financial and operational decision making and period-to-period comparisons. We believe that these non-GAAP financial measures provide useful information about operating results, enhance the overall understanding of our operating performance and future prospects, and allow for greater transparency with respect to key metrics used by senior management in our financial and operational decision making. Our non-GAAP financial measures exclude amounts that we do not consider part of ongoing operating results when planning and forecasting and when assessing the performance of the organization and our senior management. While we compute non-GAAP financial measures using a consistent method from quarter to quarter and year to year, we may consider whether other significant items that arise in the future should be excluded from our non-GAAP financial measures.

These non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles, differ from GAAP measures with the same names, and may differ from non-GAAP financial measures with the same or similar names that are used by other companies.

We believe that non-GAAP measures have limitations in that they do not reflect all of the amounts associated with our results of operations as determined in accordance with GAAP and that these financial measures should only be used to evaluate our results of operations in conjunction with the corresponding GAAP financial measures. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP information and the reconciliations between these presentations, to more fully understand our business.

Management believes organic revenue is a meaningful metric to investors as it provides a more consistent comparison of Dexcom’s revenue to prior periods as well as to industry peers. We exclude the following items from organic revenue:

  • The effect of non-CGM revenue acquired or divested in the trailing twelve months; and
  • The effect of foreign currency fluctuations

Management believes that the presentation of operating results that exclude these items provides useful supplemental information to investors and facilitates the analysis of our core operating results and comparison of operating results across reporting periods. Management believes that this supplemental non-GAAP information is therefore useful to investors in analyzing and assessing our past and future operating performance.

Table D reconciles the non-GAAP financial measures included in this press release to the most directly comparable financial measures prepared in accordance with GAAP.

Our policy is to exclude the following items from non-GAAP financial measures for non-GAAP gross profit, non-GAAP operating income, non-GAAP operating margin, non-GAAP net income, and non-GAAP diluted net income per share:

  • Amortization of acquired intangible assets;
  • Business transition and related costs associated with acquisition and divestiture, integration and business transition activities, including severance, relocation, consulting, leasehold exit costs, third-party merger and acquisition costs, and other non-recurring significant items;
  • Income or loss from equity investments, which includes realized and unrealized gains or losses from marketable and non-marketable equity securities. These amounts may reflect changes in value due to observable price changes or impairments;
  • Third-party intellectual property litigation costs in connection with Dexcom’s patent infringement litigation against Abbott Diabetes Care, Inc.;
  • Litigation settlement costs;
  • Gain or loss on extinguishment of debt; and
  • Adjustments related to taxes for the excluded items above, as well as excess benefits or tax deficiencies from share-based compensation, and the quarterly impact of other discrete items

Adjusted EBITDA excludes non-cash operating charges for share-based compensation (including equity-related charges associated with severance, restructuring, or other business transition activities), depreciation and amortization as well as non-operating items such as interest income, interest expense, gain or loss on extinguishment of debt, income or loss from equity investments, and income tax expense or benefit. For the reasons explained above, Adjusted EBITDA also excludes business transition and other significant items, litigation settlement costs, and intellectual property litigation costs.

INVESTOR RELATIONS CONTACT:
Sean Christensen
Senior Vice President - Finance and Investor Relations
[email protected]

(858) 203-6657

MEDIA CONTACT:
[email protected]

Source: DexCom, Inc.

View All News

dexcom logo

Follow us

facebook icon linkedin icon youtube icon

IR Contacts

Matt Carey

Director, Investor Relations

Joe Deltorchio

Lead Investor Relations Manager

(858) 200-0200

[email protected]

Investor Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At DexCom, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to DexCom, Inc. to send you the requested Investor Email Alert updates.

* Required

Email Address *

Investor Alert OptionsInvestor Alert Options *

News
Quarterly Reports
Annual Reports
SEC Filings
EOD Stock Quote
Events & Presentations

Submit Sign Up

Unsubscribe

Email Alert Sign Up Confirmation

1. JAMA. 2017;317(4):371-378.
2. Welsh, J.B. et al (2019). "Accuracy, Utilization, and Effectiveness Comparisons of Different Continuous Glucose Monitoring Systems." Diabetes Technol Ther 21(3) Dexcom, Dexcom G6, Dexcom Share, and Dexcom CLARITY are registered trademarks of Dexcom, Inc. in the United States and/or other countries.

*If your glucose alerts and readings from the G6 or G7 CGM Systems do not match symptoms or expectations or you’re taking over the recommended maximum dosage amount of 1000mg of acetaminophen every 6 hours, use a blood glucose meter to make diabetes treatment decisions.

© 2026 Q4 Inc. - All rights reserved

Powered By Q4 Inc. 5.191.0.1 (opens in new window)

October 28, 2026

  • The longest-lasting and most accurate1 continuous glucose monitoring (CGM) system authorized by Health Canada will offer people living with diabetes over the age of 18 up to 15.5 days of wear with fewer sensor changes.2
  • Dexcom G7 15 Day will be publicly reimbursed for many eligible Canadians living with diabetes beginning in November.
  • Private health plans that cover CGMs will be adding coverage for Dexcom G7 15 Day in November.

BURNABY, British Columbia--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that the Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) will be available in Canada beginning next month for adults 18 years and older living with diabetes. Offering up to 15.5 days of wear,2 Dexcom G7 15 Day combines industry leading sensor duration with best-in-class accuracy,1 giving Canadians living with diabetes more time between sensor changes and fewer interruptions to daily routines.

The Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) will be available in Canada beginning next month for adults 18 years and older living with diabetes.

The Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) will be available in Canada beginning next month for adults 18 years and older living with diabetes.

Importantly, broad reimbursement will be in place starting in November, helping make this advancement accessible. Dexcom G7 15 Day will be publicly reimbursed for many eligible people living with type 1 and type 2 diabetes across Canada next month. In addition, most Canadians with private health plans that currently provide CGM coverage will soon have access to the latest Dexcom CGM technology.

“For people living with diabetes, staying aware of their glucose is part of everyday life. Our goal is to make that experience simple, seamless and intuitive,” said André Côté, Vice President and General Manager, Dexcom Canada. “With Dexcom G7 15 Day, we’re delivering the longest-lasting1 sensor on the market that does not compromise on accuracy and performance. We are also focusing on launching with significant public and private reimbursement already in place, helping more Canadians benefit from this technology right away.”

Designed to help people spend less time thinking about their CGM and more time living their lives, Dexcom G7 15 Day is the longest lasting1 and most accurate1 CGM system authorized by Health Canada, providing real‑time glucose readings for an industry leading 15.5 days.1,2 With an overall MARD of 8.0%,3 the system builds on the performance of Dexcom CGM which is clinically proven to lower A1C and increase time in range.4-8

Dexcom G7 15 Day sets a new standard in CGM technology that’s easy to use, painless to insert* and requires fewer sensor changes per month.

New with Dexcom G7 15 Day

  • Longest lasting 1 CGM system with up to 15.5 days 2 of wear.
  • Best-in-class accuracy with an overall MARD of 8.0%. 1,3
  • Easier glucose management with fewer monthly sensor changes and reduced waste.

Dexcom G7 features included with Dexcom G7 15 Day

  • The only waterproof † CGMs available. 2
  • Direct to Apple Watch ‡ connectivity, so you can leave your phone behind and still see your glucose numbers.
  • 12-hour grace period to replace finished sensors for a more seamless transition between sessions.
  • Innovative and simple mobile app with Dexcom Clarity integration to easily view glucose patterns, trends and statistics for meaningful conversations with your healthcare provider. §
  • Ability to remotely share glucose numbers with caregivers and loved ones for added support and peace of mind. ||,9
  • Customizable alert settings for improved discretion and personalized diabetes management.

“Living with type 2 diabetes means there is always something to think about, whether it’s checking my glucose levels or making decisions about my health,” said Malcolm Kelly, Dexcom Warrior. “Having a CGM that lasts longer means one less thing to manage and fewer interruptions to my routine. Those small changes can make a big difference when you’re living with diabetes.”

Dexcom is working closely with its automated insulin delivery partners and looks forward to extending the launch to their customers shortly as they finalize integration.

To learn more about Dexcom G7 15 Day, visit Dexcom.com/dexcom-g7-15-day .

About Dexcom

Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in continuous glucose monitoring for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

Dexcom. Discover what you’re made of. For more information, visit www.dexcom.com .

Category: IR

* 96% of patients reported mild/no pain. † The Dexcom G7 Sensor is waterproof and may be submerged under eight feet of water for up to 24 hours without failure when properly installed. ‡ Smart devices sold separately. To view a list of compatible devices, visit dexcom.com/compatibility . Compatible smartphone is required to pair a new Dexcom G7 sensor with a compatible Apple Watch. § An internet connection is required for users to send their glucose data to Dexcom Clarity via a compatible smart device: dexcom.com/compatibility . Healthcare providers will only be able to view a patient’s glucose data if the patient elects to share it with them through Dexcom Clarity. || Separate Dexcom Follow app and internet connection required. Users should always confirm readings on the Dexcom G7 app or receiver before making treatment decisions. 1 Dexcom, Data on File, 2026. 2 Dexcom G7 15 Day User Guide. 3 Garg SK, et al. Diabetes Technol Ther. 2025;27(6):413-502. 4 Beck RW, et al_. JAMA._ 2017;317(4):371-378. 5 Beck RW, et al_. Ann Intern Med_. 2017;167(6):365-374. 6 Martens T, et al. JAMA. 2021;325(22):2262-2272. 7 Oser TK, et al. N Engl J Med. 2026. doi: 10.1056/NEJMoa2608571. Epub ahead of print. 8 Welsh JB, et al_. J Diabetes Sci Technol._ 2024;18(1):143-147. 9 Polonsky WH, Fortmann AL. Diabetes Technol Ther. 2021;23(3):195-202.

Investor Contact:
Sean Christensen
[email protected]

Media Contact:
Nadia Conard
[email protected]

Source: DexCom, Inc.

View All News

dexcom logo

Follow us

facebook icon linkedin icon youtube icon

IR Contacts

Matt Carey

Director, Investor Relations

Joe Deltorchio

Lead Investor Relations Manager

(858) 200-0200

[email protected]

Investor Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At DexCom, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to DexCom, Inc. to send you the requested Investor Email Alert updates.

* Required

Email Address *

Investor Alert OptionsInvestor Alert Options *

News
Quarterly Reports
Annual Reports
SEC Filings
EOD Stock Quote
Events & Presentations

Submit Sign Up

Unsubscribe

Email Alert Sign Up Confirmation

1. JAMA. 2017;317(4):371-378.
2. Welsh, J.B. et al (2019). "Accuracy, Utilization, and Effectiveness Comparisons of Different Continuous Glucose Monitoring Systems." Diabetes Technol Ther 21(3) Dexcom, Dexcom G6, Dexcom Share, and Dexcom CLARITY are registered trademarks of Dexcom, Inc. in the United States and/or other countries.

*If your glucose alerts and readings from the G6 or G7 CGM Systems do not match symptoms or expectations or you’re taking over the recommended maximum dosage amount of 1000mg of acetaminophen every 6 hours, use a blood glucose meter to make diabetes treatment decisions.

© 2026 Q4 Inc. - All rights reserved

Powered By Q4 Inc. 5.191.0.1 (opens in new window)

October 14, 2026

  • Publication marks the first time in nearly two decades that The New England Journal of Medicine has published clinical data on standalone real-time continuous glucose monitoring (CGM) technology, dating back to the creation of the CGM category.

  • Randomized controlled trial demonstrates Dexcom G7 significantly reduces A1C and improves glucose control compared with routine care.

  • Benefits observed across a broad range of participants, including those taking GLP-1 medications.1

  • Findings support the role of CGM earlier in Type 2 diabetes care for all people, including those over the age of 65.

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc.

(NASDAQ: DXCM), the global leader in glucose biosensing, today announced that results from the landmark CONNECT randomized controlled trial have been published in The New England Journal of Medicine (NEJM), providing rigorous evidence of the significant benefits of continuous glucose monitoring (CGM) for adults with Type 2 diabetes not on insulin.

Randomized controlled trial demonstrates Dexcom G7 significantly reduces A1C and improves glucose control compared with routine care.

CONNECT participants using Dexcom G7 experienced an average 1.6% A1C reduction from a mean baseline of 8.8%, a 0.9% greater A1C reduction compared with routine care.1 Participants using Dexcom G7 also spent approximately five additional hours per day in the glucose target range of 70–180 mg/dL compared with those receiving routine care.1

“Publication of CONNECT in The New England Journal of Medicine represents a significant moment for the CGM category. Nearly two decades after NEJM last published clinical data on real-time CGM, we now have compelling evidence demonstrating the impact this technology can have for the millions of people with Type 2 diabetes who are not using insulin,” said Jake Leach, president and CEO of Dexcom. “Dexcom has spent more than 25 years building the CGM category, and today the evidence is undeniable. We’re calling on physicians, payors and healthcare leaders to recognize the meaningful impact CGM can have for this population and help bring the benefits of this technology to millions more people around the world."

The benefit of CGM use was observed across a broad range of baseline characteristics, including age, sex, race and ethnicity, body mass index, diabetes duration, income, education, health insurance and glucose-lowering medications. Among participants using GLP-1 therapies, wearing Dexcom G7 resulted in an additional 0.9% A1C reduction compared with routine care.1

“These results provide compelling evidence that CGM use can meaningfully improve glucose outcomes for people with Type 2 diabetes who are not using insulin,” said Roy W. Beck, MD, PhD, Medical Director of the JAEB Center for Health Research and senior author of the study. “The fact that almost all participants were still using CGM after 26 weeks and most were using it every day indicates that the participants recognized the benefit of CGM and incorporated it into their daily diabetes management. Furthermore, the consistency of benefit across a broad range of people and treatment regimens supports consideration of the use of a CGM much earlier in Type 2 diabetes management before insulin is needed.”

The CONNECT study screened 440 participants across 22 primary care sites in the United States. The findings were first presented at the American Diabetes Association’s 2026 Scientific Sessions and add to a growing body of evidence supporting broader access to CGMs for people with Type 2 diabetes.

Key CONNECT Findings

  • Participants using Dexcom G7 experienced an average 1.6% A1C reduction from a mean baseline of 8.8%, a 0.9% greater reduction than routine care.

  • 68% of participants using Dexcom G7 achieved an A1C below 7.5%, and 46% achieved an A1C below 7.0% at 26 weeks.

  • Dexcom G7 users spent approximately five additional hours per day in the 70–180 mg/dL glucose target range compared with routine care.

  • Improvement in this glucose target range was observed within the first week of CGM use.

  • Among all participants, the largest difference between treatment-group and control came among those on a GLP-1 medication only at baseline (-1.3% delta between CGM and Control).

  • Among participants using GLP-1 therapies, CGM resulted in an additional 0.9% A1C reduction versus routine care.

  • After 26 weeks, 97% of participants were still using CGM, most on a daily basis.

The full study is available on The New England Journal of Medicine website

Prompts

DexCom, Inc. (ticker DXCM), listed in United States.

ETFs Holding DexCom, Inc.

ETF Weight in ETF Shares Market value As of
TMFM 5.89% 77,077 $ 7.019M Aug 31, 2026
LGHT 4.01% 1,473 $ 99.207K Jun 30, 2026
GDOC 3.86% 8,317 $ 757.346K Aug 31, 2026
TMFG 2.82% 109,830 $ 10.001M Aug 31, 2026
JMID 2.74% 7,762 $ 647.739K Jul 31, 2026
BMED 2.21% 3,881 $ 316.728K Nov 16, 2026
FGSI 1.83% 465 $ 37.36K Nov 11, 2026
HRTS 1.82% 11,085 $ 1.009M Aug 31, 2026
TLG 1.76% 35,535 $ 2.393M Jun 30, 2026
SAGP 1.69% 19,178 $ 1.292M Jun 30, 2026
MID 1.51% 17,334 $ 1.578M Aug 31, 2026
TMED 1.46% 4,976 $ 335.134K Jun 30, 2026
AGRW 1.28% 17,329 $ 1.446M Jul 31, 2026
LGRO 1.15% 18,009 $ 1.64M Aug 31, 2026
MMID 1.06% 4,208 $ 383.18K Aug 31, 2026
FWD 1.03% 362,927 $ 33.048M Aug 31, 2026
RILA 1.01% 5,118 $ 427.097K Jul 31, 2026
BRCE 0.99% 4,006 $ 364.786K Aug 31, 2026
AVMV 0.92% 93,446 $ 7.626M Nov 16, 2026
SMIZ 0.83% 24,927 $ 2.27M Aug 31, 2026
SHRT 0.75% 1,180 $ 96.3K Nov 17, 2026
TCAL 0.74% 29,984 $ 2.447M Nov 17, 2026
FMED 0.71% 4,000 $ 364.24K Aug 31, 2026
TMAT 0.66% 18,766 $ 1.566M Jul 31, 2026
REMC 0.59% 294 $ 19.801K Jun 30, 2026
QIDX 0.55% 2,575 $ 214.884K Jul 31, 2026
AVLV 0.52% 1,453,822 $ 118.646M Nov 16, 2026
SXQG 0.45% 3,269 $ 266.064K Nov 12, 2026
AVMC 0.43% 29,178 $ 2.381M Nov 16, 2026
VFQY 0.42% 23,742 $ 2.162M Aug 31, 2026
AVUQ 0.39% 20,421 $ 1.667M Nov 16, 2026
FEMG 0.38% 378 $ 25.458K Jun 30, 2026
LQAI 0.37% 100 $ 8,139.00 Nov 12, 2026
SPIN 0.35% 1,919 $ 156.61K Nov 16, 2026
AIVL 0.30% 18,586 $ 1.252M Jun 30, 2026
RGLO 0.28% 13,754 $ 926.332K Jun 30, 2026
ESUM 0.23% 4,954 $ 413.411K Jul 31, 2026
LGDX 0.21% 3,482 $ 284.166K Nov 17, 2026
ESLG 0.20% 561 $ 46.815K Jul 31, 2026
JEPQ 0.20% 981,825 $ 80.549M Nov 17, 2026
SFGV 0.20% 28,245 $ 2.32M Nov 18, 2026
MCDS 0.18% 177 $ 14.521K Nov 17, 2026
AFGR 0.16% 1,629 $ 132.943K Nov 16, 2026
AVSU 0.16% 9,695 $ 791.209K Nov 16, 2026
AVLC 0.16% 30,986 $ 2.529M Nov 16, 2026
AVUS 0.15% 268,889 $ 21.944M Nov 16, 2026
HBTA 0.13% 3,456 $ 314.703K Aug 31, 2026
TUGN 0.12% 1,432 $ 96.445K Jun 30, 2026
CAPE 0.12% 4,193 $ 282.399K Jun 30, 2026
GQI 0.09% 3,292 $ 221.716K Jun 30, 2026
DFSU 0.08% 23,782 $ 1.936M Nov 12, 2026
AAUS 0.08% 4,772 $ 390K Nov 18, 2026
IALT 0.07% 67,259 $ 5.489M Nov 16, 2026
DFVX 0.07% 4,807 $ 391.242K Nov 12, 2026
TUG 0.06% 318 $ 21.417K Jun 30, 2026
DFAC 0.06% 652,947 $ 53.143M Nov 12, 2026
THRO 0.06% 72,135 $ 5.887M Nov 16, 2026
JUSA 0.06% 6,327 $ 519.067K Nov 17, 2026
DUHP 0.06% 134,063 $ 10.911M Nov 12, 2026
MODL 0.05% 8,323 $ 560.554K Jun 30, 2026
ACVF 0.05% 912 $ 76.106K Jul 31, 2026
VOXP 0.05% 33 $ 2,753.85 Jul 31, 2026
DXUV 0.05% 35,901 $ 2.922M Nov 12, 2026
APUE 0.05% 12,441 $ 1.133M Aug 31, 2026
DFAU 0.05% 72,100 $ 5.868M Nov 12, 2026
DFUS 0.04% 118,270 $ 9.626M Nov 12, 2026
TACU 0.04% 99 $ 8,079.39 Nov 17, 2026
GDE 0.04% 2,193 $ 199.695K Aug 31, 2026
XMAG 0.04% 1,165 $ 94.819K Nov 13, 2026
DYNF 0.04% 179,833 $ 14.676M Nov 16, 2026
HCMT 0.04% 2,682 $ 223.813K Jul 31, 2026
NTSD 0.04% 204 $ 13.739K Jun 30, 2026
VSLU 0.04% 2,983 $ 200.905K Jun 30, 2026
NTSX 0.03% 7,083 $ 477.04K Jun 30, 2026
MSLC 0.03% 14,956 $ 1.362M Aug 31, 2026
DCOR 0.03% 159,994 $ 13.022M Nov 12, 2026
RAA 0.02% 1,672 $ 112.609K Jun 30, 2026
CSHP 0.01% 634 $ 51.741K Nov 16, 2026
ENHU 0.01% 17 $ 1,387.37 Nov 16, 2026
GSPY 0.01% 1,197 $ 97.687K Nov 17, 2026
FRTY 0.00% 85 $ 5,724.75 Jun 30, 2026
EBI 0.00% 138 $ 12.566K Aug 31, 2026
CORO 0.00% 238 $ 19.423K Nov 16, 2026